The Autopsy / Case File · Overdose & Substance
Kratom
It grows as a tree in Southeast Asia, gets ground into a powder or pressed into capsules, and sits on the counter at gas stations, vape shops, and smoke shops across most of the United States next to the energy drinks and rolling papers. No prescription, no age check in most states, no federal safety threshold. And it keeps turning up in the toxicology reports of people who died of an overdose.
A CDC surveillance study of 27 states found kratom, or its active alkaloid mitragynine, present in the postmortem toxicology of 152 unintentional or undetermined-intent overdose deaths over an 18-month window — and a medical examiner or coroner determined kratom was a cause of death, not just a bystander substance in the blood, in 91 of those cases. Nearly two-thirds involved fentanyl. Seven people had nothing else in their system at all.
Join the discussion →
Kratom occupies a strange regulatory position in American drug policy: not a controlled substance under federal law, not an FDA-approved supplement or medication either, sold almost everywhere as an herbal product under the same loose framework that governs protein powder and multivitamins. Millions of Americans use it, by most industry estimates, for pain relief, opioid withdrawal management, energy, or mood — a self-medication market that exists largely because the alternatives (prescription opioids, formal addiction treatment, or nothing) are expensive, restricted, or unavailable. The plant's two primary active alkaloids, mitragynine and 7-hydroxymitragynine, bind to the same opioid receptors that heroin, fentanyl, and prescription painkillers act on, which is exactly why it can relieve pain and ease withdrawal — and exactly why it carries overdose risk that a "natural supplement" label doesn't warn anyone about.
What the CDC's 27-State Data Actually Found
The benchmark data comes from a CDC Notes from the Field report published in the Morbidity and Mortality Weekly Report on April 12, 2019, drawing on the State Unintentional Drug Overdose Reporting System (SUDORS) — the same detailed, case-level surveillance infrastructure the CDC uses to track the broader opioid crisis, built on postmortem toxicology and death-scene investigation data supplied by medical examiners and coroners in participating states. Across July 2016 through December 2017, SUDORS states recorded 27,338 unintentional or undetermined-intent overdose deaths. Kratom, or mitragynine specifically, was detected on toxicology in 152 of them — a small fraction, 0.56 percent, of the total. But detection and cause are two different findings, and the report's more significant number is the second one: in 91 of those 152 cases, a medical examiner or coroner reviewed the case and formally determined kratom was a cause of death, not merely present. Seven of those 91 had no other substance detected at all — kratom, alone, ruled the cause.
The demographic profile skewed heavily toward what toxicologists sometimes call the "self-medicating" overdose population rather than the profile associated with illicit fentanyl deaths broadly: about three-quarters male, over 90 percent white, and — in a detail the report's authors flagged as notable — 90.8 percent of kratom-involved decedents had no evidence of ever having been under a doctor's care for pain management. Four in five had a documented history of substance misuse. The picture that emerges isn't of a party drug or a street-fentanyl substitute so much as a self-treatment product, taken by people managing pain or withdrawal on their own, outside any clinical structure that might have caught a dangerous interaction before it became fatal.
The Company It Keeps
Most kratom-involved deaths weren't kratom acting alone. Among the 91 cases where kratom was ruled a cause of death, fentanyl or a fentanyl analog was also listed as a cause in 56.0 percent, heroin in 25.3 percent, benzodiazepines in 26.4 percent, prescription opioids in 24.2 percent, and cocaine in 16.5 percent. That polysubstance pattern matters for two separate reasons. First, it means kratom is increasingly entering the same contaminated, unpredictable illicit and gray-market supply that has made fentanyl the dominant driver of American overdose deaths generally — someone buying a kratom product has no more assurance of what's actually in it, in what concentration, than someone buying counterfeit pills. Second, it means the pharmacological danger compounds: mitragynine, like other opioid-receptor agonists, suppresses breathing, and combining it with benzodiazepines or additional opioids multiplies that respiratory-depression risk in exactly the way that makes routine polysubstance opioid combinations so lethal.
The naloxone question is where kratom's regulatory gap becomes a genuine clinical problem rather than just a labeling one. Naloxone, the opioid-overdose reversal drug now stocked in pharmacies, schools, and police cruisers nationwide, works by displacing opioids from the same receptors mitragynine binds to — which means it has some theoretical and case-reported effect in a kratom-involved overdose. But kratom's alkaloids don't behave identically to classic opioids at the receptor level, dosing guidance for a kratom-specific reversal scenario doesn't formally exist, and a bystander or first responder recognizing a kratom overdose in progress — as opposed to a more familiar heroin or pill overdose — is a much harder ask when the product came in an unmarked capsule bought at a gas station counter.
It's sold next to the energy drinks and the rolling papers, with no age check in most states and no dose printed on the label that means anything clinically. The receptor it binds to doesn't care that the package says "supplement."
A Regulatory Fight the FDA Keeps Losing
The FDA has never approved kratom for any medical use and has repeatedly warned, going back over a decade, that it carries risks of abuse, addiction, and death — but the agency's authority to actually restrict it has run into a wall of political and consumer pushback every time it's been tested. In 2016, the DEA moved to temporarily place kratom's two main alkaloids in Schedule I, the same category as heroin, citing an "imminent hazard to public safety." The proposal drew tens of thousands of public comments, a bipartisan congressional letter opposing it, and a formal petition campaign from kratom advocacy groups arguing the plant was a lifeline for people managing chronic pain or tapering off opioids without it. The DEA withdrew the scheduling notice within two months and has not revived it. In the years since, roughly two dozen states have instead passed their own Kratom Consumer Protection Acts — a patchwork approach that sets age minimums and some labeling or purity standards state by state, while a handful of states and municipalities have banned the product outright and the rest regulate it not at all.
What's shifted the FDA's posture more recently isn't the traditional leaf-and-powder kratom market the 2019 CDC surveillance was built on — it's a newer category of product concentrating 7-hydroxymitragynine, the more potent of kratom's two primary alkaloids, into tablets, gummies, drink shots, and even novelty items sold at the same gas stations and vape shops. Naturally occurring kratom leaf contains only trace amounts of 7-hydroxymitragynine; these newer "7-OH" products are synthesized or chemically concentrated to deliver far higher doses, marketed with the same loose "natural supplement" branding as traditional kratom despite pharmacology closer to a synthetic opioid. In 2025, the FDA sent warning letters to multiple companies marketing 7-OH products, citing reports linking them to respiratory depression, seizures, liver toxicity, and deaths, and announced steps to restrict their sale — treating them, functionally, as an emerging opioid threat wearing kratom's old regulatory camouflage. Whether that enforcement effort meaningfully changes what's available at the counter, or simply prompts another rebranding the way the 2016 scheduling fight didn't stop the broader kratom market, is still an open question the CDC's next surveillance cycle will have to answer.
A Coroner's Problem, Not Just a Regulator's
Underneath the federal back-and-forth sits a narrower, more immediate problem for the people whose job is to actually rule on a death: kratom doesn't fit neatly into the standard toxicology screening panels most medical examiner's offices run by default. Mitragynine testing typically requires a specific, separately requested assay rather than showing up on a routine broad-spectrum drug screen, which means a jurisdiction that doesn't think to test for it — or can't afford to — may simply never know it was there. The CDC's own surveillance authors have noted this as a likely source of undercounting in the 152-death figure, not an overcount: SUDORS' 27 participating states in 2016-2017 didn't include every state, and even within participating states, kratom-specific testing wasn't universal. The number that made it into the MMWR is very likely a floor, not a ceiling, on how often kratom is actually present when Americans die of an overdose — a gap that, unlike scheduling status or state consumer-protection laws, is a laboratory-capacity and protocol problem no legislature can vote to fix.
And Then You're Dead
Nobody buying a capsule at a gas station counter is told what receptor it's about to bind to, or that the same emergency-room drug used to reverse a heroin overdose might not fully work on this one. The label says supplement. The body, when the dose is wrong or the batch is contaminated, doesn't know the difference.
That's it. That's the whole thing.
Sources
- The 152 kratom-positive overdose deaths, 91 kratom-involved (cause-of-death) deaths, 7 kratom-only deaths, demographic breakdown, and co-occurring-substance percentages (fentanyl 56.0%, heroin 25.3%, benzodiazepines 26.4%, prescription opioids 24.2%, cocaine 16.5% among kratom-involved cases) across 27 SUDORS-reporting states, July 2016–December 2017 — Olsen EO, O'Donnell J, Mattson CL, Schier JG, Wilson N, "Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected — 27 States, July 2016–December 2017," MMWR Morbidity and Mortality Weekly Report, April 12, 2019;68(14):326-327
- FDA's regulatory history and current public health position on kratom, including its longstanding warnings on abuse and death risk — "FDA and Kratom," U.S. Food and Drug Administration, Public Health Focus
- The 2025 FDA warning letters to firms marketing concentrated 7-hydroxymitragynine (7-OH) products, citing reports of respiratory depression, seizures, liver toxicity, and death, and the agency's steps to restrict these products — "FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers" and "FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine," U.S. Food and Drug Administration press announcements, 2025
- The 2016 DEA notice of intent to temporarily schedule kratom's primary alkaloids as Schedule I substances and its withdrawal following public and congressional opposition — Drug Enforcement Administration Federal Register notice and subsequent withdrawal, 2016
- State-by-state Kratom Consumer Protection Act adoption and the absence of federal regulation — state legislative tracking of kratom regulatory status
- Photo: "Kratom leaves.jpg," Thehealingeast, CC BY-SA 4.0, via Wikimedia Commons
Comments
Loading…